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Abstract 
Endometriosis is a benign gynecologic disease characterized by the presence of 
ectopic endometrium and associated with inflammation and immune 
abnormalities. However, the molecular basis for endometriosis is not well 
understood. To address this issue, the present study examined the expression of 
high-mobility group box (HMGB)1 in menstrual blood to investigate its role in the 
ectopic growth of human endometriotic stromal cells (ESCs). A total of 139 
patients were enrolled in this study; 84 had endometriosis, and 55 were 
non-endometriotic gynecological patients (control). HMGB1 levels in various 
fluids were measured by enzyme-linked immunosorbent assay. Expression of 
receptor for advanced glycation end products (RAGE) in eutopic and ectopic 
endometrium was assessed by immunohistochemistry, and RAGE and vascular 
endothelial growth factor (VEGF) mRNA expression in HMGB1- and 
lipopolysaccharide (LPS)-treated endometriotic stromal cells (ESCs) was 
evaluated by real-time PCR. HMGB1 concentration was higher in menstrual 
blood than in serum or peritoneal fluid (P < 0.001 for both). RAGE was 
expressed in both normal and ectopic endometrium. Administration of 1000 
ng/ml HMGB1 or co-administration of 100 ng/ml HMGB1 and 100 ng/ml LPS 
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induced VEGF production in ESCs relative to the control (P < 0.05). These 
results suggest that menstrual fluid has naturally high levels of HMGB1 and may 
promote endometriosis following retrograde menstruation when complexed with 
other factors such as LPS by inducing inflammation and angiogenesis. 
Key words: endometriosis, high-mobility group box 1, lipopolysaccharide, 
receptor for advanced glycation end products, vascular endothelial cell growth 
factor 
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Introduction 
Endometriosis is a common, benign gynecologic disease characterized by the 
presence of ectopic endometrium that causes dysmenorrhea, chronic pelvic pain, 
and infertility, and associated with inflammation and immune abnormalities as 
well as changes in ovarian steroid hormone output. The growth and 
maintenance of endometrial and endometriotic tissues is regulated by several 
cytokines and growth factors such as interleukin (IL)-6, IL-8, tumor necrosis 
factor (TNF)-α, and vascular endothelial growth factor (VEGF).1,2 Retrograde 
menstruation into the peritoneal cavity via the fallopian tubes is thought to play 
an important role in the pathogenesis of endometriosis.3 Menstrual fluid consists 
of blood cells, endometrial tissue, and debris, which are sources of endometrial 
cells. However, the profile of bioactive molecules in menstrual blood is unclear. 
High-mobility group box (HMGB)1 is an abundant non-histone component 
of chromatin expressed in almost all nucleated mammalian cells. HMGB1 is 
mainly present in the nucleus and regulates DNA transcription, repair, replication, 
and remodeling.4 However, it is also a late mediator of inflammation; in 
inflammatory events such as injury, infection, or cell necrosis, HMGB1 is 
passively released from necrotic cells or secreted by activated cells of the innate 
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immune system into the extracellular milieu. HMGB1 has little or no 
proinflammatory activity in itself but forms complexes with proinflammatory 
factors such as IL-1 or lipopolysaccharide (LPS) and thereby potentiates their 
biological activities. Thus, HMGB1 complexes stimulate the synthesis of 
proinflammatory cytokines and activate innate immunity and inflammation by 
binding to receptor for advanced glycation end products (RAGE) and Toll-like 
receptors (TLRs) 2, 4, and 9.5–8 HMGB1 is also a potent proangiogenic factor 
that acts via RAGE and TLR4 signaling pathways; it stimulates endothelial cell 
proliferation and induces the release of proangiogenic cytokines such as VEGF, 
TNF-α, and IL-8 from endothelial cells and macrophages.9,10 We speculate that 
HMGB1 or its complexes in menstrual blood induces inflammation and 
angiogenesis to promote the progression of endometriosis. 
To investigate the role of HMGB1 in endometriosis, we measured HMGB1 
concentrations in peripheral and menstrual blood and peritoneal fluid, as well as 
RAGE expression in normal endometrium and peritoneal endometriosis. We 
also evaluated the direct effect of HMGB1 and its complexes on human 
endometriotic stromal cells (ESCs) by measuring VEGF mRNA levels. 
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Materials and methods 
Study population 
A total of 139 patients who were not undergoing hormonal therapy were enrolled 
in this study, including 84 with endometriosis and 55 with benign gynecologic 
diseases other than endometriosis (control) (Table 1). Exclusion criteria were 
pregnancy, diabetes, cardiovascular disease, cancers, active pelvic 
inflammatory disease, or any other acute or chronic inflammatory disease. 
All patients underwent laparoscopic surgery or hysterectomy at the 
Department of Obstetrics and Gynecology, Okayama University Hospital. Written, 
informed consent was obtained from each patient before the start of the study, 
and the protocol was approved by the Institutional Review Board of Okayama 
University Hospital (no. d07001). The menstrual phase was determined based 
on basal body temperature and histological analysis of the endometrium. Most 
patients had regular cycles. Staging and morphological characterization of 
peritoneal endometriotic lesions were based on the revised classification of The 
American Society of Reproductive Medicine (Re-ASRM, 1996). Lesions were 
diagnosed by their macroscopic appearance and categorized as red or black 
according to the latest revision of the ASRM classification.11 
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Preparation of body fluid samples 
Peripheral blood samples (endometriosis, n = 6 and control, n = 15) were 
obtained from patients on days 3–5 of the menstrual cycle and delivered to the 
laboratory within 30 min of collection. Peripheral blood was immediately 
centrifuged at 1500 × g for 10 min, and the supernatant was stored at −30°C 
until use. 
Menstrual blood samples (endometriosis, n = 13 and control, n = 14) were 
obtained from patients on days 3–5 of the menstrual cycle. In the lithotomy 
position, an 18-gauge blunt-tip needle connected to a 1-ml plastic syringe was 
inserted into the uterine cervix to collect menstrual blood by manual suction. The 
blood was carefully diluted twice with phosphate-buffered saline (PBS) and then 
immediately centrifuged at 1000 × g for 10 min. The supernatant was stored at 
−30°C until use. 
Peritoneal fluid samples were collected during laparoscopic surgery from 
48 patients with endometriosis and nine control patients without endometriosis in 
the mid-proliferative phase of the menstrual cycle. Samples were centrifuged at 
1000 × g for 10 min and the supernatant was stored at −30°C until use. 
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Preparation of tissue samples 
Peritoneal endometriosis tissue samples were removed laparoscopically in the 
mid-proliferative phase of the menstrual cycle from 36 patients. Normal 
endometrial tissue samples were obtained from 23 hysterectomy patients with 
other benign gynecologic disease and without endometriosis. The walls of 
endometrial ovarian cysts were removed laparoscopically from four patients. 
Enzyme-linked immunosorbent assay (ELISA) 
HMGB1 levels in serum, menstrual blood, and peritoneal fluid were measured 
using ELISA kits (Shino-Test Corporation, Kanagawa, Japan) according to the 
manufacturer’s protocols. The two-step sandwich ELISA employed 96-well 
microtiter assay plates where each well was pre-coated with a polyclonal 
antibody specific for HMGB1. Briefly, 10 μl of sample (i.e., standard, serum, 
peritoneal fluid, or 10 fold-diluted menstrual blood) and 100 μl of dilution buffer 
were added to each well; after mixing by shaking, the plate was incubated for 24 
h at 37°C. Wells were then washed five times with wash solution. After 
incubation at room temperature for 2 h with 100 μl peroxidase-linked 
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anti-HMGB1 monoclonal antibody solution, the wells were washed five times 
with wash solution. A 100-µl mixture of equal volumes of tetramethyl benzidine 
and buffer containing 5 mM hydrogen peroxide was then added to each well at 
regular time intervals with incubation at room temperature for 30 min. The 
reaction was terminated by adding 100 μl sulfuric acid (0.35 mol/l), and 
absorbance at 450 nm was read on a Model 680 microplate reader (Bio-Rad, 
Osaka Japan). 
Immunohistochemistry 
Tissue samples (endometriosis, n = 36 and normal endometrium, n = 23) were 
fixed in 10% buffered formalin for 48 h. The tissue was embedded in paraffin, cut 
into 4-µm-thick sections, and mounted on silanized slides. Sections were stained 
with hematoxylin and eosin (Merck, Darmstadt, Germany) for histological 
analysis. For immunohistochemistry, slides were processed with the 
peroxidase-conjugated streptavidin-biotin system using diaminobenzidine (DAB) 
as a chromogen (labeled streptavidin-biotin kit; Dako, Carpinteria, CA, USA) 
according to the manufacturer’s instructions. Briefly, sections were treated with 
3% H2O2 for 5 min to quench endogenous peroxidase activity. After blocking 
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nonspecific staining (Protein Block Serum-Free; Dako), sections were incubated 
with 2 μg/ml of anti-RAGE antibody (H-300 rabbit polyclonal IgG antibody; Santa 
Cruz Biotechnology, Dallas, Texas, USA) for 90 min at 37°C followed by 
biotinylated anti-rabbit immunoglobulin secondary antibody (Dako) for 20 min at 
room temperature. A cervical intraepithelial neoplasia sample was used to 
prepare a positive control slide for RAGE immunolabeling.12 As a negative 
control, preimmune rabbit serum was used instead of the primary antibody. After 
staining with DAB, sections were counterstained with Mayer’s hematoxylin 
solution (Merck). Immunoreactivity was scored as follows: 0, no staining; 1, 
weak; 2, same as positive control; 3, strong. Sections with a score of ≥ 2 were 
defined as positive. Scoring was independently performed by two researchers in 
at least three high-power (400×) fields. 
ESC culture 
ESCs were isolated from endometrial ovarian cyst biopsy specimens by 
selective enzyme digestion and filtration as previously described.13 The cells 
were resuspended at a density of approximately 106 cells/ml of Dulbecco’s 
modified Eagle’s medium/F-12 containing 10% fetal bovine serum (Gibco BRL, 
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Grand Island, NY, USA) and 100 IU/ml penicillin-streptomycin (Invitrogen, 
Carlsbad, CA, USA), and grown to confluence for approximately 72 h at 37°C in 
a humidified atmosphere of 5% CO2. ESCs were stimulated with 100 or 1000 
ng/ml recombinant HMGB1 (Sigma-Aldrich, St. Louis, MO, USA) and then 
incubated with different doses (1–100 ng/ml) of LPS (Sigma-Aldrich) for 24 h. 
Real-time PCR 
VEGF and RAGE mRNA levels were evaluated 24 h after ESCs were exposed to 
HMGB1 and LPS. ESCs were harvested and rinsed twice with PBS, and total 
RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany). 
Real-time PCR was carried out using the iTaq Universal SYBR Green One-Step 
kit and Mini Opticon reader (Bio-Rad); 1 μl of the product was used in a final 
volume of 20 μl according to the manufacturer’s instructions. Human-specific 
sense and antisense primers used in for target gene amplification were as 
follows: VEGF, 5′-GCAGAAGGAGGAGGGCAGAAT-3′ and 5′
-GTCTCGATTGGATGGCAGTAGC-3′; RAGE, 5′
-CAGGATGAGGGGATTTTC-3′ and 5′-AGGAATCTGGTAGACACG-3′; 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5′
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-GATGACATCAAGAAGGTGGTGAA-3′ and 5′
-GTCTTACTCCTTGGAGGCCATGT-3′ (all from Sigma-Aldrich).14 VEGF and 
RAGE mRNA expression levels against the reference GAPDH were calculated 
with the 2−ΔΔCT method. Amplification was performed over 40 cycles under the 
following conditions: 50°C for 10 min, 95°C for 1 min, 95°C for 10 s, and 60°C for 
20 s. 
Statistical analysis 
Differences between groups were evaluated with the Mann-Whitney U test and 
one-way analysis of variance. Data were analyzed with SPSS Statistics 20 
software (IBM, Armonk, NY, USA). A P value < 0.05 was statistically significant. 
Results 
HMGB1 is highly expressed in menstrual blood 
HMGB1 concentration was higher in menstrual blood than in serum or peritoneal 
fluid (P < 0.001 for both). However, there was no significant difference between 
endometriosis and control groups with respect to HMGB1 concentrations in 
serum, peritoneal fluid, and menstrual blood (serum: 29.3 ± 18.4 vs. 22.0 ± 9.4 
14 
ng/ml, n = 6 and 15, respectively; peritoneal fluid: 71.4 ± 68.1 vs. 68.7 ± 43.9 
ng/ml, n = 48 and 9, respectively; menstrual blood: 667.1 ± 631.4 vs. 914.8 ± 
844.0 ng/ml, n = 13 and 14, respectively) (Fig. 1A). When the endometriosis 
group was stratified according to disease severity, we found no differences 
among the ASRM I-II, ASRM III-IV, and control groups in terms of HMGB1 
concentration in peritoneal fluid (ASRM I-II: 84.8 ± 60.6 ng/ml, n = 16; ASRM 
III-IV: 64.6 ± 71.5 ng/ml, n = 32; control: 68.7 ± 43.9 ng/ml, n = 9) (Fig. 1B). 
RAGE is highly expressed in normal endometrium and peritoneal endometriosis 
RAGE was expressed throughout the menstrual cycle in normal endometrium. In 
the proliferative phase of the cycle, RAGE-positive cells were detected in the 
glandular epithelium and stromal cells in 90.9% (10/11) and 72.7% (8/11) of 
samples, respectively (Fig. 2A). In the secretory phase of the cycle, 
RAGE-positive cells were present in the glandular epithelium and stromal cells in 
90.0% (9/10) and 80.0% (8/10) of samples, respectively (Fig. 2B). In red lesions 
of peritoneal endometriosis, RAGE was expressed in glandular and stromal cells 
in 100% (10/10) and 86.4% (19/22) of samples, respectively (Fig. 2C). In black 
lesions, RAGE expression was detected in glandular and stromal cells in 100% 
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(14/14) and 87.5% (14/16) of samples, respectively (Fig. 2D). 
Co-administration of HMGB1 and LPS induces VEGF production 
Treatment of ESCs with 1000 ng/ml HMGB1 induced VEGF production as 
compared to cells treated with 100 ng/ml HMGB1 or untreated cells (P < 0.05 
and 0.05, respectively) (Fig. 3A). VEGF production was not induced by 
administration of 100 ng/ml HMGB1 alone but was observed upon 
co-administration of 100 ng/ml HMGB1 and 100 ng/ml LPS (P < 0.05) (Fig. 3B). 
RAGE mRNA level was unaltered in the presence of HMGB1 (Fig. 3C) and LPS 
(data not shown). 
Discussion 
This is the first report of elevated HMGB1 levels in menstrual blood as compared 
to the levels in peritoneal fluid or serum. We demonstrated that recombinant 
HMGB1 and LPS increased VEGF mRNA expression in ESCs. HMGB1 
expression is clinically associated with the onset of sepsis, systemic 
inflammatory response syndrome, disseminated intravascular coagulation, 
cancer progression, arteriosclerosis, and ischemia-reperfusion injury. Serum 
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HMGB1 concentration is low in healthy individuals, but is upregulated in 
gastric,15 colon,16 and cervical17 cancers and sepsis-induced organ dysfunction.5 
Hypoxia was shown to cause an increase in extracellular HMGB1 level in 
synovial fibroblast cells obtained from a patient with rheumatoid arthritis; 
additionally, the level was higher in the synovial fluid of patients with rheumatoid 
arthritis as compared to those with osteoarthritis (inflammatory vs. 
non-inflammatory arthropathy).18
A recent study reported HMGB1 secretion in human endometrial stromal 
cells following H2O2-induced cell necrosis. In addition, cell proliferation was 
increased in a concentration- and time-dependent manner by treatment with 
recombinant HMGB1.19 Menstruation is a monthly hypoxic event in the 
endometrium caused by steroid hormone withdrawal; HMGB1 may consequently 
be released from necrotic endometrial cells. Indeed, our results demonstrate the 
extremely high concentration of HMGB1 in menstrual blood. 
There was no difference in peritoneal fluid or menstrual blood HMGB1 
concentrations between women with and without endometriosis. HMGB1 in 
peritoneal fluid with endometriosis may originate from ectopic endometrium, but 
an extremely high HMGB1 concentration in menstrual blood that refluxes into 
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the peritoneal cavity was presumed to influence HMGB1 level in peritoneal fluid 
in the mid-proliferative phase of the menstrual cycle, making it difficult to 
independently evaluate HMGB1 in peritoneal fluid. 
HMGB1 stimulates proangiogenic cytokines such as VEGF via RAGE and 
TLR4 signaling pathways.9,10 Endometriosis is a focal and chronic inflammatory 
disease; VEGF is also an angiogenic factor that likely modulates vascularization 
in endometriosis.1 HMGB1 in menstrual blood that refluxes into the peritoneal 
cavity is thought to modulate angiogenesis in endometriosis via VEGF induction. 
We found in this study that RAGE is expressed in the normal 
endometrium of the human uterus as well as the ectopic endometrium in 
peritoneal endometriosis. RAGE is a multi-ligand receptor for nonenzymatic 
glycation and oxidation products of proteins and lipids. RAGE activation by 
ligand binding stimulates diverse signaling cascades via transcription factors 
such as nuclear factor-κB.20The HMGB1/RAGE inflammatory pathway promotes 
pancreatic tumor growth by enhancing tumor cell mitochondrial complex I activity, 
ATP production, and tumor cell proliferation and migration;21 moreover, 
alterations in human endothelial cell function in the pathogenesis of lupus 
vasculitis also involve signaling through this pathway.22 
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Retrograde menstruation has been implicated in the pathophysiology and 
pathogenesis of endometriosis.3 We speculate that the extremely high 
concentration of HMGB1 that is expected in retrograde menstruation based on 
the current results promotes peritoneal seeding with viable endometrial cells, 
and subsequent development of endometriosis by induction of inflammation and 
angiogenesis via RAGE expressed in eutopic and ectopic endometrium. 
HMGB1 has little or no proinflammatory activity on its own, but forms 
complexes with and increases the activity of exogenous or endogenous 
proinflammatory molecules.6,7 Co-treatment of endometrial epithelial cells with 
LPS and HMGB1 was shown to increase TLR4 gene expression and 
consequently, IL-8 production.23 In synovial fibroblasts co-cultured with the 
HMGB1-LPS complex, RAGE, TLR2, and TLR4 expression levels were 
upregulated relative to untreated cells.24 We also demonstrated that VEGF 
mRNA expression was not induced by administration of 100 ng/ml HMGB1 alone 
but was observed upon co-administration of 100 ng/ml HMGB1 and 100ng/ml 
LPS. 
It is well known that retrograde menstruation frequently occurs in women, 
but does not always lead to endometriosis. Furthermore, we did not find any 
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difference in menstrual blood HMGB1 concentrations between women with and 
without endometriosis. On the other hand, the menstrual blood of the former 
group shows greater contamination with E. coli and correspondingly higher 
levels of endotoxin than that of control women. It has been suggested that 
bacterial contamination promotes LPS/TLR4-mediated growth of 
endometriosis.25 We therefore suggest that there are differences in HMGB1 
complex formation with LPS or other molecules or in their affinity for receptors 
between women with and without endometriosis. 
In conclusion, we report high levels of HMGB1 in menstrual blood and of 
RAGE in both eutopic and ectopic endometrium. We also confirmed that 
combined application of HMGB1 and LPS induced VEGF mRNA expression in 
human ESCs. These findings support our hypothesis that HMGB1 or its 
complexes promote the development of endometriosis following retrograde 
menstruation by inducing inflammation and angiogenesis, although further 
research is needed to clarify the molecular mechanisms involved. 
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Table 1. Patient characteristics 
n Age 
mean ± SD (range) 
BMI 
mean ± SD (range) 
Endometriosis 
Re-ASRM I-II 
Re-ASRM III-IV 
Control 
84 
33 
51 
55 
34.4 ± 5.4 (21–46) 
32.0 ± 6.5 (19–44) 
21.1 ± 3.0 (15.9–35.7) 
21.2 ± 3.5 (14.9–32.0) 
BMI = body mass index; Re-ASRM = revised classification of peritoneal 
endometriotic lesions of The American Society of Reproductive Medicine. 
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Figure legends 
Figure 1. HMGB1 concentrations in body fluids. 
HMGB1, a nuclear protein released to the extracellular compartment by necrotic 
cells. (A) HMGB1 concentrations in serum, menstrual blood, and peritoneal fluid. 
Bars show the group means. HMGB1 level was higher in menstrual blood than in 
the other fluids. (B) Comparison of HMGB1 concentration in peritoneal fluid 
among patients with two grades of endometriosis and control subjects. Bars 
show the group means. There was no difference in HMGB1 concentration 
among groups. Re-ASRM = revised classification of peritoneal endometriotic 
lesions of The American Society of Reproductive Medicine. 
Figure 2. RAGE expression in normal endometrium and peritoneal 
endometriosis. 
(A, B) RAGE-positive cells (brown) were detected in glandular epithelium and 
stromal cells of the normal endometrium in proliferative (A) and secretory (B) 
phases of the menstrual cycle. Hematoxylin-stained nuclei are blue. (C, D) 
RAGE expression was also detected in glandular and stromal cells in red (C) 
and black (D) lesions of peritoneal endometriosis. 
Figure 3. Effect of HMGB1 on VEGF and RAGE mRNA expression in 
endometriotic stromal cells. 
(A) Administration of 1000 ng/ml HMGB1 induced VEGF production in ESCs 
relative to cells treated with 100 ng/ml HMGB1 and untreated control cells. *P < 
0.05. (B) Co-administration of HMGB1 (100 ng/ml) and LPS (100 ng/ml) induced 
27 
VEGF production. (C) RAGE mRNA level was unaltered by HMGB1 
administration. Data are expressed as mean ± SD. 
